A Study of RC48-ADC in Subjects With HER2 Overexpressed Metastatic Biliary Tract Cancer
Clinical trial NCT04329429 · UNKNOWN
Trial details
- NCT number
- NCT04329429
- Sponsor
- RemeGen Co., Ltd.
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2020-08-24
- Primary completion
- 2023-11-03
- Enrollment
- 57
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.